Akwai ci gaba na baya-bayan nan a cikin ciwon daji na huhu mara ƙanƙanta. Wani irin rigakafi wanda zai iya magance ƙananan ƙwayar cutar huhu (NSCLC) ya sami ƙwarewa na asibiti na 3 kuma yana da babban tasirin ilimin likita akan ƙananan ƙwayoyin huhu. Yanzu yana da sauƙi a cikin fewan ƙasashe kaɗan.
As an anti-idiotype monoclonal antibody, the vaccine enables lung cancer patients to respond strongly to specific glycosylated gangliosides (NeuGcGM3) in cancer cells. Compared with the best supportive care, lung maganin ciwon daji na iya inganta ƙimar rayuwa na marasa lafiya tare da matakin sake dawowa da ci gaba (mataki IIIB / IV) NSCLC.
Rather than numerous warm blooded creatures, including gorillas, we can’t recognize the nearness of NeuGcGM3 gangliosides in typical human tissues and liquids. Be that as it may, NeuGcGM3 gangliosides are profoundly communicated in certain human malignant growth cells. In non-little cell lung malignancy tests, gangliosides were identified in over 90% of non-little cell lung tumors. Thusly, NeuGcGM3 ganglioside can be utilized as a ground-breaking objective for lung malignant growth antibodies.
Bayan tsarin da ba za a iya fahimta ba ya samar da kwayoyin kariya ga an maganin rigakafi, yana iya ƙirƙirar ƙwayoyin cuta kan keɓancewa da keɓaɓɓiyar antigen, wanda zai iya sarrafa tsarin juriya daga ciki. Dangane da yin allurar rigakafi game da wannan haɓakar ƙwayar cutar huhun rigakafi, it can advance the generation of antibodies against this antigen, assigned Ab1. These Ab1 antibodies are fit for delivering a progression of hostile to idiotypic antibodies, assigned Ab2. The idiotypes of these exceptional antibodies are fused into the antigen-restricting site of Ab1, with the goal that these extraordinary antibodies produce a particular resistant reaction to regular antigens. Hence, vaccination with Ab2 immunizer can advance the creation of Ab3 (hostile to against idiotype neutralizer), and this Ab3 counter acting agent can perceive the first antigen perceived by Ab1. Some Ab2 antibodies of this sort invigorate the safe framework to actuate defensive resistance against tumo antigens.
An tabbatar da asibiti cewa cutar huhu rigakafi an jimre shi sosai kuma yafi kyau aiwatarwa. Yawancin alamomi na asali suna faruwa ne kawai a cikin gida (rukunin jiko) kuma suna da ladabi da ɗan gajeren tsawo. Ba tare da la'akari da ko an ba marasa lafiya maganin ba bayan da yanayin su ya watse, jimiri gaba ɗaya ya inganta.
A halin yanzu, ba a inganta irin wannan rigakafin ciwon huhu mai cutar huhu a Indiya.
